Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

68 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
NRF2 and cancer: the good, the bad and the importance of context.
Sporn MB, Liby KT. Sporn MB, et al. Nat Rev Cancer. 2012 Jul 19;12(8):564-71. doi: 10.1038/nrc3278. Nat Rev Cancer. 2012. PMID: 22810811 Free PMC article. Review.
NRF2 as an Emerging Therapeutic Target.
Copple IM, Dinkova-Kostova AT, Kensler TW, Liby KT, Wigley WC. Copple IM, et al. Oxid Med Cell Longev. 2017;2017:8165458. doi: 10.1155/2017/8165458. Epub 2017 Jan 31. Oxid Med Cell Longev. 2017. PMID: 28250892 Free PMC article. No abstract available.
Nrf2-Dependent and -Independent Effects of tert-Butylhydroquinone, CDDO-Im, and H2O2 in Human Jurkat T Cells as Determined by CRISPR/Cas9 Gene Editing.
Zagorski JW, Maser TP, Liby KT, Rockwell CE. Zagorski JW, et al. J Pharmacol Exp Ther. 2017 May;361(2):259-267. doi: 10.1124/jpet.116.238899. Epub 2017 Mar 9. J Pharmacol Exp Ther. 2017. PMID: 28280124 Free PMC article.
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
Leal AS, Williams CR, Royce DB, Pioli PA, Sporn MB, Liby KT. Leal AS, et al. Cancer Lett. 2017 May 28;394:76-87. doi: 10.1016/j.canlet.2017.02.021. Epub 2017 Feb 27. Cancer Lett. 2017. PMID: 28254412
PARP inhibitors for chemoprevention--reply.
To C, Sporn MB, Liby KT. To C, et al. Cancer Prev Res (Phila). 2014 Nov;7(11):1172. doi: 10.1158/1940-6207.CAPR-14-0264. Cancer Prev Res (Phila). 2014. PMID: 25368012 No abstract available.
Is lycopene an effective agent for preventing prostate cancer?
Sporn MB, Liby KT. Sporn MB, et al. Cancer Prev Res (Phila). 2013 May;6(5):384-6. doi: 10.1158/1940-6207.CAPR-13-0026. Epub 2013 Mar 12. Cancer Prev Res (Phila). 2013. PMID: 23483003
Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762.
Zhang D, Leal AS, Carapellucci S, Zydeck K, Sporn MB, Liby KT. Zhang D, et al. Cancer Prev Res (Phila). 2018 Mar;11(3):143-156. doi: 10.1158/1940-6207.CAPR-17-0264. Epub 2017 Dec 15. Cancer Prev Res (Phila). 2018. PMID: 29246957
The triterpenoid CDDO-imidazolide reduces immune cell infiltration and cytokine secretion in the KrasG12D;Pdx1-Cre (KC) mouse model of pancreatic cancer.
Leal AS, Sporn MB, Pioli PA, Liby KT. Leal AS, et al. Carcinogenesis. 2016 Dec;37(12):1170-1179. doi: 10.1093/carcin/bgw099. Epub 2016 Sep 22. Carcinogenesis. 2016. PMID: 27659181 Free PMC article.
CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages.
Ball MS, Shipman EP, Kim H, Liby KT, Pioli PA. Ball MS, et al. PLoS One. 2016 Feb 26;11(2):e0149600. doi: 10.1371/journal.pone.0149600. eCollection 2016. PLoS One. 2016. PMID: 26918785 Free PMC article.
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, Hu H, Schiff R, Cook RS, Kurokawa M. Canfield K, et al. Cell Cycle. 2015;14(4):648-55. doi: 10.4161/15384101.2014.994966. Cell Cycle. 2015. PMID: 25590338 Free PMC article.
68 results
Jump to page